UROV - Urovant Sciences: Buyout Price Is Too Low

• The acquisition of Urovant Sciences by majority owner Sumitomo significantly undervalues the company's lead asset vibegron.
• The buyout price implies approximately $250 million in peak sales for vibegron in the OAB market.
• Other shots on goal for vibegron and the company's second asset URO902 are not receiving any credit at $16.25 per share.
• On the other hand, the buyout ahead of the expected approval of vibegron removes the regulatory and commercial launch risks.
• The approval of the majority of minority shareholders is needed to close the acquisition.

For further details see: